TapImmune Inc. (NASDAQ:MRKR) has received a consensus broker rating score of 1.50 (Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. One investment analyst has rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. TapImmune’s rating score has improved by 40% in the last 90 days as a result of various analysts’ upgrades and downgrades.
Brokers have set a 1 year consensus price target of $7.50 for the company and are anticipating that the company will post ($0.21) earnings per share for the current quarter, according to Zacks. Zacks has also assigned TapImmune an industry rank of 72 out of 255 based on the ratings given to its competitors.
A number of research analysts have recently weighed in on MRKR shares. Nomura started coverage on TapImmune in a research report on Wednesday, November 21st. They set a “buy” rating and a $16.00 price objective for the company. ValuEngine upgraded TapImmune from a “hold” rating to a “buy” rating in a research report on Saturday, January 5th. Piper Jaffray Companies started coverage on TapImmune in a research report on Monday, October 22nd. They set a “neutral” rating for the company. Finally, Zacks Investment Research lowered TapImmune from a “buy” rating to a “hold” rating in a research report on Wednesday, January 16th.
TapImmune (NASDAQ:MRKR) last posted its quarterly earnings results on Tuesday, November 13th. The company reported ($0.32) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.44) by $0.12. As a group, research analysts forecast that TapImmune will post -1.13 EPS for the current year.
Several institutional investors have recently modified their holdings of MRKR. NEA Management Company LLC purchased a new position in shares of TapImmune during the fourth quarter valued at about $27,750,000. Neville Rodie & Shaw Inc. purchased a new position in shares of TapImmune during the fourth quarter valued at about $167,000. Riggs Asset Managment Co. Inc. purchased a new position in shares of TapImmune during the fourth quarter valued at about $151,000. Finally, Personal Capital Advisors Corp purchased a new position in shares of TapImmune during the fourth quarter valued at about $143,000. Hedge funds and other institutional investors own 14.25% of the company’s stock.
Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its cell therapy technology is based on the tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets.
See Also: Depreciation
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TapImmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TapImmune and related companies with MarketBeat.com's FREE daily email newsletter.